Stenting Of Symptomatic Cerebral siNus stenosIs With the laserCut Self-expanding SILANCE Stent

NCT07561268 | Not Yet Recruiting

• 1 other identifier: SONIC
• Study Type: interventional
• Target: 99
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objective of this clinical investigation is to evaluate and demonstrate the clinical benefit, performance, and safety of the SILANCE Stent, which is specifically designed for the treatment of patients with symptomatic sinus stenoses associated with IIH.

Conditions

Idiopathic Intracranial Hypertension (IIH)

Keywords

Symptomatic venous sinus stenosis; IIH; Sinus stenosis; Lateral Sinus Stenosis; Sinus Stenting; Idiopathic intracranial hypertension

Outcome Measures

Primary Outcomes (3)

• Rate of patients with disappearance or significant improvement of IIH related symptoms at first follow-up

  The disappearance or significant improvement of symptoms related to venous sinus stenosis at the first follow-up (6 months) will be evaluated as follows: 1 Headaches will be assessed using the Headache Impact Test (HIT-6). The scale consists of six items with five-point response options and yields a total score ranging from 36 to 78, with higher scores indicating greater headache-related impairment. 2\. Pulsatile tinnitus will be assessed using the Tinnitus Functional Index (TFI). The Tinnitus Functional Index (TFI) is a validated 25-item patient-reported measure of tinnitus severity across eight domains, yielding a total score from 0 to 100 (higher scores indicating greater severity). 3\. Visual impairment will be assessed using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25).It consists of 25 items across multiple subscales and provides subscale as well as an overall score ranging from 0 to 100, where higher scores indicate better vision-related quality.

  6 months

• Number of patients with disappearance or a clinically significant reduction of the transstenotic venous pressure gradient following implantation of the SILENCE stent.

  Venous pressure is measured at at least two locations: proximal (upstream) to the stenosis at the torcular Herophili and distal (downstream) to the stenosis at the jugular bulb. Only patients demonstrating a venous pressure gradient of \> 3 mmHg under general anesthesia and \> 4 mmHg under local anesthesia are eligible for inclusion in the study. The pressure gradient is assessed both before and after stent implantation. A reduction in the pressure gradient is considered indicative of achieving the efficacy endpoint.

  Periprocedural

• Rate of major adverse events at 6 months (± 3) months and 12 (±3) months

  MAEs are defined as symptomatic, serious, procedure- or device-related post-procedure complications: major stroke, neurological death, in-stent thrombosis, target vessel restenosis, stent-adjacent stenosis, or stent migration.

  6 months and 12 months

Study Arms (1)

Implantation of SILANCE Stent / Elimination of the lateral sinus stenosis

EXPERIMENTAL

Device: SILANCE Stent Implantation

Interventions

SILANCE Stent Implantation DEVICE

Endovascular treatment of the lateral sinus stenosis is performed using the SILANCE stent with the aim of eliminating the stenosis and achieving resolution of the associated clinical symptoms.

Implantation of SILANCE Stent / Elimination of the lateral sinus stenosis

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of idiopathic intracranial hypertension (IIH) according to the Modified Dandy Criteria.
• Cerebrospinal fluid (CSF) lumbar puncture opening pressure \> 25 cm H₂O.
• Presence of lateral venous sinus stenosis confirmed by venous magnetic resonance angiography (MRA) or venous computed tomography angiography (CTA).
• Presence of clinical symptoms consistent with IIH, including headaches, visual field loss, papilledema or pulsatile tinnitus.
• Venous pressure gradient across the stenosis \> 3 mmHg under general anaesthesia, \> 4 mmHg under local anaesthesia.
• Temporal Bone CT done for Patients suffering from Pulsatile Tinnitus
• Written informed consent obtained prior to any study-related procedures.

Sponsors & Collaborators

• Acandis GmbH: lead

MeSH Terms

Conditions

Pseudotumor Cerebri

Condition Hierarchy (Ancestors)

Intracranial Hypertension; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Central Study Contacts

Anna Gold

CONTACT

+49 7231 155000; info@acandis.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 27, 2025
• First Posted: May 1, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): October 1, 2028
• Study Completion (Estimated): October 1, 2029
• Last Updated: May 1, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share